Onco Preventer

Category: Uncategorized

  • Onco-Innovations CEO Discusses Breakthroughs in Cancer Treatment and AI Integration

    Компания Onco-Innovations Limited, занимающая лидирующие позиции в области лечения онкологических заболеваний, недавно привлекла внимание широкой аудитории благодаря подробному интервью с генеральным директором Томасом О'Шонесси, которое состоялось в рамках программы «Разговоры, которые имеют значение». В ходе беседы господин О’Шонесси подробно рассказал о прорывных достижениях компании в терапии рака, особо подчеркнув инновационное использование искусственного интеллекта (ИИ) для улучшения результатов лечения. Этот шаг открывает новые горизонты в медицинской науке и демонстрирует, как современные технологии способны изменить устоявшиеся подходы к борьбе с такими сложными заболеваниями, как рак.

    Особое внимание в интервью было уделено разработке новых методов лечения колоректального рака и других солидных опухолей. Колоректальный рак — один из самых распространённых и труднопрогнозируемых видов онкологических заболеваний в мире, с высокой смертностью. Исследовательский портфель компании включает передовые методики, которые направлены на преодоление сложностей, связанных с этим типом рака, благодаря чему возможно существенно улучшить прогнозы для пациентов. Например, использование ИИ помогает выявлять мельчайшие отклонения в генетическом материале опухолей, что позволяет глубже понять особенности их развития и подобрать наиболее эффективные варианты терапии. Кстати, знаете ли вы, что ИИ в онкологии способен анализировать тысячи потенциальных комбинаций лекарств за считанные минуты, чего просто невозможно добиться вручную? Это не только ускоряет процесс, но и значительно повышает шансы на успех лечения.

    Одним из ключевых моментов интервью стала стратегическая покупка компании Inka Health AI, специализирующейся на технологиях искусственного интеллекта. Эта сделка подтверждает намерения Onco-Innovations интегрировать ИИ в свои исследовательские и производственные процессы. Благодаря этому объединению компания рассчитывает продвинуть точную медицину вперед, разрабатывая терапии, адаптированные под индивидуальные генетические особенности пациентов и характеристики их опухолей. Такой персонализированный подход не только увеличивает эффективность лечения, но и помогает минимизировать нежелательные побочные эффекты. Забавный факт: исследования показывают, что в ближайшие годы ИИ может стать настолько точным, что для составления плана лечения будет достаточно одного анализа крови — без болезненных биопсий и долгих ожиданий результатов!

    Важной составляющей успеха Onco-Innovations является её активное сотрудничество с различными научно-исследовательскими институтами и фармацевтическими компаниями. Эти партнерства позволяют объединить опыт, ресурсы и инновационные технологии, что ускоряет разработку и внедрение новых методов лечения. Совместная работа создает более надежную научную базу и способствует тому, что открытия становятся доступными для широкой аудитории пациентов в кратчайшие сроки. Кроме того, такие коллаборации стимулируют кросс-дисциплинарные исследования, которые открывают неожиданные перспективы не только в онкологии, но и в других областях медицины. Например, применённые ИИ-методы могут впоследствии использоваться для разработки новых лекарств против нейродегенеративных заболеваний или аутоиммунных расстройств.

    В целом, Onco-Innovations Limited выходит на передовой рубеж в развитии революционных методов борьбы с раком. Использование передовых технологий искусственного интеллекта совместно с активной научной и промышленной кооперацией позволяет компании создавать максимально эффективные и персонализированные лекарственные средства для пациентов с колоректальным и другими солидными опухолями. Лидерство Томаса О'Шонесси в этих стремлениях подчеркивает важность инновационного подхода и точной медицины, способной изменить будущее онкологического лечения. Работы и партнерства компании вселяют уверенность в том, что в ближайшем будущем станет возможным не только значительно улучшить выживаемость пациентов, но и существенно повысить качество их жизни.

    #Онкология #ИскусственныйИнтеллект #ТочнаяМедицина #РакКишечника #ИнновацииВМедицине #OncoInnovations #БудущееЛечения

    Source

  • Onco-Innovations CEO Discusses Breakthroughs in Cancer Treatment and AI Integration

    Компания Onco-Innovations Limited продолжает впечатлять мировое научное и медицинское сообщество своими передовыми открытиями в области онкологии, укрепляя статус лидера инновационных разработок в лечении рака. Недавнее интервью с генеральным директором Томасом О’Шонесси в программе «Беседы, которые имеют значение» открыло нам возможность взглянуть за кулисы удивительных научных прорывов компании. В эпоху, когда границы медицины и высоких технологий стираются, Onco-Innovations создаёт уникальный мир, где страшный диагноз превращается не в приговор, а в временное испытание, с которым можно и нужно бороться. Это смелое видение будущего медицины задаёт тон всему направлению, где технологии становятся союзниками в борьбе с одной из самых опасных болезней человечества.

    Особое внимание в работе компании уделяется колоректальному раку – одной из самых распространённых и смертельно опасных форм онкологических заболеваний. Эта разновидность рака отличается высокой степенью сложности в лечении и требует комплексного и многогранного подхода, включающего инновационные препараты, современные методы терапии и персонализированные стратегии взаимодействия с пациентом. Onco-Innovations стремится к тому, чтобы максимально точно исследовать индивидуальные характеристики каждой опухоли, ведь только индивидуализированный подбор методов лечения способен обеспечить наилучший баланс между эффективностью и минимальными побочными эффектами. Благодаря такому подходу пациенты отмечают, что лечение становится не столь травматичным, а путь к выздоровлению – более достижимым. По данным Всемирной организации здравоохранения, колоректальный рак занимает третье место по распространённости среди мужчин и второе среди женщин, что подчёркивает критическую важность разработок компании в этой области.

    Революционный рывок в деятельности Onco-Innovations стал возможен благодаря приобретению компании Inka Health AI, специализирующейся на использовании искусственного интеллекта в медицинских исследованиях. Эта сделка значительно расширила возможности Onco-Innovations в создании сложных систем анализа и обработки данных о пациентах, охватывающих весь спектр – от генетического профиля до биомаркеров опухолей. Внедрение ИИ позволяет выявлять ключевые особенности раковых клеток и создавать максимально эффективные и щадящие терапевтические протоколы, адаптированные под конкретные медицинские случаи. Не менее интересно, что современные алгоритмы искусственного интеллекта способны обрабатывать потрясающие объёмы информации, превосходящие человеческие возможности в сотни тысяч раз, что радикально меняет диагноз и методики лечения. Это приводит к существенному повышению шансов на успех в борьбе с заболеванием и значительному снижению рисков и тяжести побочных реакций, которые зачастую сопровождают традиционные методы терапии.

    Кроме того, искусственный интеллект становится ключевым инструментом не только в совершенствовании существующих методов лечения, но и в ускорении разработки новых лекарств. Анализ массивов данных, автоматизированное выявление биомаркеров и перспективных терапевтических мишеней помогает значительно сократить время клинических испытаний и концентрировать ресурсы на наиболее перспективных направлениях. Такой глубоко междисциплинарный и международный подход подразумевает тесное сотрудничество ведущих мировых исследовательских центров и фармацевтических компаний, тем самым открывая двери к качественно новым этапам развития медицинской науки в онкологии. По мнению экспертов, применение ИИ может снизить сроки появления новых препаратов с традиционных 10–15 лет до 3–5, что поистине является технологической революцией и вселяет настоящую надежду для миллионов больных во всём мире.

    Генеральный директор Onco-Innovations Томас О’Шонесси подчёркивает, что миссия компании простирается далеко за пределы традиционного здравоохранения. В основе их работы лежит стремление стать мировым лидером в области персонализированной терапии рака, объединив современные технологии и практики здравоохранения для создания решений, делающих лечение более эффективным, комфортным и безопасным для пациентов. Благодаря таким революционным подходам мир постепенно приближается к моменту, когда диагноз рак перестанет быть смертельным приговором, а станет всего лишь очередным этапом на пути к выздоровлению. Более того, уникальные разработки Onco-Innovations имеют потенциал трансформировать и другие медицинские направления, открывая новые горизонты в диагностике и терапии, что поспособствует формированию более здорового и долгоживущего общества.

    #OncoInnovations #ИскусственныйИнтеллект #ЛечениеРака #ПерсонализированнаяМедицина #КолоректальныйРак #ИнновацииВОнкологии #БорьбаСРаком

    Source

  • 3 Things You Should Know About Advances in CLL Management

    RELEASE DATE: May 1, 2025

    EXPIRATION DATE: May 1, 2026

    LEARNING OBJECTIVES

    Upon successful completion of this activity, you should be better prepared to:

    Assess the role of risk stratification, MRD assessment, and resistance mechanisms in treatment selection and personalization for patients with CLL across multiple therapy lines.

    Analyze trial results from studies that evaluated BCL2 inhibitor– based strategies in patients with CLL across all therapy lines.

    Devise effective strategies to monitor and mitigate treatment-related toxicities in patients with CLL.

    Accreditation/Credit Designation

    Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Acknowledgment of commercial support

    This activity is supported by an educational grant from AbbVie Inc.

    Off-label disclosure/disclaimer

    This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this activity is for accredited continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER or any company that provided commercial support for this activity.

    Instructions for participation/how to receive credit

    Read this activity in its entirety.

    Go to https://www.gotoper.com/cll25management-postref to access and complete the posttest.

    Answer the evaluation questions.

    Request credit using the drop-down menu.

    YOU MAY IMMEDIATELY DOWNLOAD YOUR CERTIFICATE.

    Management of patients with chronic lymphocytic leukemia (CLL) has been transformed in recent years by novel targeted therapies that disrupt B-cell receptor signaling. Continuous treatment with the first-generation Bruton tyrosine kinase (BTK) inhibitor ibrutinib, once the paradigm, has been replaced by second-generation BTK inhibitors acalabrutinib and zanubrutinib, and the BCL2 inhibitor venetoclax, with the anti-CD20 monoclonal antibody obinutuzumab as preferred first-line therapy (Table 1).1 Although BTK inhibitors are generally given continuously, venetoclax with obinutuzumab is a time-limited regimen.2,3 Care for patients continues to evolve. Here are 3 things you should know when treating patients with CLL.

    1. Time-limited doublet and triplet therapy are being evaluated.

    Currently, there is no single standard frontline treatment for patients with CLL. Ultimately, therapy selection is based on factors including genetic risk markers, patient comorbidities, comedications, preference, and logistics.4 Doublet therapy, which combines a BTK or BCL2 inhibitor with an anti-CD20 monoclonal antibody or a BTK inhibitor with a BCL2 inhibitor, has been evaluated with promising results.5 Notably, the BCL2/BTK inhibitor combination has resulted in deep and durable remissions in a time-limited approach.6,7

    Novel triplet combinations for CLL include a BTK inhibitor, BCL2 inhibitor, and anti-CD20 monoclonal antibody.5 Results from the phase 3 AMPLIFY study (NCT03836261) were recently reported. In AMPLIFY, patients with CLL who did not have a deletion of chromosome 17p (del[17p]) or TP53 mutation were randomly assigned to the combination of time-limited venetoclax/acalabrutinib/obinutuzumab, acalabrutinib/venetoclax, or chemoimmunotherapy (investigator’s choice of fludarabine/cyclophosphamide/rituximab or bendamustine/rituximab). Rates of undetectable measurable residual disease (MRD) in the intent-to-treat were highest in patients treated with the triplet regimen (Figure).8 With a median follow-up of 40.8 months, the 3-year progression-free survival rate was 76.5% with the doublet, 83.1% with the triplet, and 66.5% with chemoimmunotherapy. The estimated 3-year overall survival rate was 94.1% with the doublet, 87.7% with the triplet, and 85.9% with chemoimmunotherapy (Table 2).8 The most common grade 3 or higher adverse event was neutropenia, which occurred in 32.3% of patients receiving the doublet, 46.1% of patients receiving the triplet, and 43.2% receiving chemotherapy.

    Updated NCCN Guidelines now list venetoclax plus acalabrutinib with or without obinutuzumab as category 1 preferred regimens for first-line therapy in patients without del(17p) or TP53 mutation.1

    2. The role of MRD in decision-making is being assessed.

    MRD assessment has become a valuable prognostic tool in CLL, but it is not yet approved to guide altering therapy outside of clinical trials. Achieving undetectable MRD at the end of treatment correlates with longer progression-free survival (PFS). Moreover,undetectable MRD4 (MRD levels <10–4)at the end of treatment with chemoimmunotherapy or time-limited treatment with a BCL2 inhibitor–containing regimen improves survival.1

    Trials such as CAPTIVATE (phase 2; NCT02910583) have explored MRD-guided continuation of treatment, but with current standard practice MRD does not yet guide treatment.9,10

    3. Adverse events still shape outcomes.

    Ultimately, keeping patients with CLL on these new lifesaving treatments requires vigilance in managing and mitigating toxicities. It is important to recognize risks of adverse events and provide appropriate mitigation. For example, venetoclax requires step-up dosing to prevent tumor lysis syndrome. Some key adverse events are included in Table 3.11 The incidence of adverse events may increase when agents are combined. Notably, rates of cytopenias, especially neutropenia, are substantially increased in combination treatment with a BTK inhibitor, BCL2 inhibitor, and anti-CD20 monoclonal antibody.5 Recognition and appropriate mitigation andmanagement of adverse events are crucial and can lead to improved quality and quantity of life.

    Key References

    1. NCCN. Clinical Practice Guidelines in Oncology. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 3.2025. Accessed April 11, 2025. https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf

    4. Tausch E, Schneider C, Stilgenbauer S. Risk-stratification in frontline CLL therapy: standard of care.Hematology Am Soc Hematol Educ Program. 2024;2024(1):457-466. doi:10.1182/hematology.2024000656

    12. Brown JR, Seymour JF, Jurczak W, et al; AMPLIFY Investigators. Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. N Engl J Med. 2025;392(8):748-762. doi:10.1056/NEJMoa2409804

    For full reference list, visit https://www.gotoper.com/cll25management-postref

    CME Posttest Questions

    1. A 48-year-old man with treatment-naive CLL without del(17p) or TP53 mutation undergoes time-limited therapy with venetoclax and obinutuzumab. At the end of treatment, he remains positive for measurable residual disease (MRD) by 6-color flow cytometry at a sensitivity of 10⁻⁵. Which of the following statements is most accurate regarding the clinical implications of his MRD status?

    1. These results should not be used because MRD assessment using flow cytometry is not valid in CLL.

    2. His MRD positivity at the 10⁻⁵ threshold is associated with an increased risk of disease progression, but it does not mandate immediate re-treatment.

    3. Because he lacks high-risk genetic features, MRD positivity after time-limited treatment does not impact long-term prognosis.

    4. Given these results, he should immediately begin treatment with a BTK inhibitor.

    2. Which of the following statements is correct regarding results from the AMPLIFY study, which compared acalabrutinib plus venetoclax (AV) with or without obinutuzumab (O) to chemoimmunotherapy in treatment-naive CLL?

    1. The undetectable MRD rate at the end of therapy was significantly higher with AV compared with chemoimmunotherapy.

    2. There was no difference in the rates of undetectable MRD.

    3. Independent Review Committee (IRC)–assessed PFS was significantly higher with AV or AVO compared with chemoimmunotherapy.

    4. There was no difference in IRC-assessed PFS between AV or AVO and chemoimmunotherapy.

    3. In studies of triplet therapy treatment (BTK inhibitor, venetoclax, and obinutuzumab) in CLL, which of the following treatment-related adverse events was most common?

    1. Grade 3 or higher atrial fibrillation

    2. Grade 3 or higher infection

    3. Grade 3 or higher neutropenia

    4. Grade 3 or higher thrombocytopenia

    Claim your CME credit at https://www.gotoper.com/cll25management-postref

    To learn more about this topic, including information on the latest clinic trial data in CLL, go to https://www.gotoper.com/cll25management-activity

    CME Provider Contact information

  • ASTRO Survey Underscores Damaging Impact of Continued Medicare Cuts on Cancer Care; Bipartisan ROCR Act Offers Solutions | Newswise

    In the ever-evolving landscape of cancer treatment, radiation therapy stands as a lifeline for over a million Americans annually. Yet, recent national survey data released by the American Society for Radiation Oncology (ASTRO) paints a worrying picture for the future. The survey, conducted among 675 radiation oncologists across the United States, reveals a near-unanimous concern: further reductions in Medicare reimbursement rates for radiation therapy are poised to significantly hinder patient access, increase wait times, and force many clinics to downsize or even close. With 96% of respondents warning about the adverse impact on patient access, and 70% anticipating a substantial deterioration, the stakes could not be higher for cancer patients relying on these crucial services.

    The implications of these reimbursement cuts are particularly dire for rural areas and independent, freestanding treatment centers. Approximately one-third of rural physicians and nearly 40% of those at independent clinics anticipate that an additional 3-5% cut would compel them to consolidate, leave, sell, or shutter their practices altogether. This is a devastating prospect because, as many know, rural communities already face significant healthcare access challenges, including longer travel distances to specialized care and fewer available specialists. Moreover, clinics are bracing for reductions in staff and experiencing increasing difficulties in hiring and retaining skilled workers—problems exacerbated by financial strains. Technology upgrades, vital for delivering state-of-the-art cancer care, are also expected to decline sharply, with 87% of doctors stating that funding cuts would delay or prevent investments in new treatment technologies.

    Since 2013, Medicare reimbursement for radiation therapy has plummeted by 25%, a decline sharper than most other medical specialties. This trend coincides with rising operational costs and a shift within radiation oncology toward shorter, more effective treatment regimens. These shorter regimens, endorsed by clinical guidelines, not only improve patient quality of life by reducing the number of visits but also present a paradox in the current fee-for-service reimbursement model, which favors volume over value. The Radiation Oncology Case Rate (ROCR) Act, introduced on Capitol Hill by a bipartisan group of lawmakers, aims to address these challenges by transitioning Medicare payment from a volume-based system to a value-based, bundled payment approach centered around individualized treatment plans. Advocates argue that implementing ROCR will preserve access to high-quality care, promote evidence-based practice, and ultimately improve patient outcomes by fostering more efficient, patient-centered treatment paths.

    The importance of legislative intervention goes beyond reimbursement models. Radiation oncologists are also voicing strong calls for reforming Medicare Advantage’s prior authorization processes, which currently contribute to treatment delays and administrative burdens. In a separate 2024 survey, a staggering 92% of radiation oncologists reported that prior authorization protocols delayed the initiation of cancer treatment, often by a week or more, exacerbating patient anxiety and potentially compromising outcomes. Troublingly, one-third of providers witnessed cases where these delays led to adverse events, including hospitalizations. Despite these onerous processes, research indicates that prior authorization requirements in Medicare Advantage fail to yield cost savings and may, in fact, increase overall expenditures. Furthermore, most denials—about two-thirds—are eventually overturned, suggesting inefficiency and unnecessary hurdles in the system. ASTRO is actively advocating for bipartisan legislation aimed at streamlining prior authorization to reduce these barriers for patients and providers alike.

    While navigating these immediate challenges, radiation oncologists also emphasize the critical role of sustained and enhanced federal cancer research funding. Over the past 30 years, bipartisan federal investments in cancer research have driven a remarkable 34% reduction in cancer mortality, saving nearly four million lives in the United States. These funds not only fuel innovations in radiation therapy and other treatment modalities but also yield significant economic returns, with every federal dollar invested in research generating $2.56 in economic activity. Radiation oncologists urge Congress to ensure robust, inflation-adjusted funding for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and emerging entities like the Advanced Research Projects Agency for Health (ARPA-H). Such support is instrumental in developing cutting-edge therapies, improving treatment efficacy, and enhancing patient quality of life. The medical community and patient advocates alike recognize that this investment is vital to maintaining momentum against cancer and bridging the gap between groundbreaking research and clinical practice.

    The landscape of cancer care is at a crossroads. Radiation therapy, a cornerstone of treatment for many cancer types, faces financial and operational threats that could impact millions of Americans. However, through informed legislation such as the ROCR Act and bipartisan efforts to eliminate administrative barriers like prior authorization delays, there is hope for a resilient future. Furthermore, a continued commitment to funding research will fuel the innovations needed to defeat cancer and improve the survivorship experience. As ASTRO and its partners continue to engage Congress and stakeholders, patients, providers, and the broader oncology community eagerly await policies that will stabilize and strengthen access to high-quality, affordable cancer care nationwide.

    #RadiationOncology #CancerCare #MedicareReform #HealthcareLegislation #CancerResearch #PatientAccess #MedicareAdvantage

    Source

  • Low-to-Moderate Agreement Seen for Diagnosing Breast Cancer-Related Lymphedema

    Diagnosing breast cancer-related lymphedema (BCRL) presents a challenging puzzle in the medical community, as revealed by a recent study published in the April issue of Rehabilitation Oncology. Cheryl L. Brunelle, P.T., of Massachusetts General Hospital, led researchers in evaluating how well various diagnostic tools and thresholds agree when identifying BCRL in patients who have undergone breast cancer treatment. The study's findings uncover a concerning inconsistency among measurement methods, highlighting the urgent need for standardized diagnostics regarding this often debilitating condition.

    Breast cancer-related lymphedema occurs when lymph fluid accumulates, typically in an arm or hand, after lymph node removal or damage during cancer treatment. This swelling can be painful and physically limiting, impacting quality of life significantly. The standard tools for diagnosing BCRL include tape measurements of limb circumference, optoelectronic limb volumetry, and bioimpedance spectroscopy (BIS), a technology that measures fluid levels in tissues using electrical currents. Brunelle’s team examined 60 patients employing these four measurement techniques, comparing diagnostic thresholds such as relative volume change (RVC) of 10 percent or greater, absolute volume differences, and L-Dex scores—BIS-based indices reflecting fluid accumulation levels.

    Out of 57 participants analyzed, about 37 percent were diagnosed with BCRL using the RVC ≥10 percent criterion, which marks a 10 percent or more increase in limb volume relative to baseline measurement. However, when preoperative baselines were included, the agreement between various diagnostic criteria dropped dramatically. For example, the agreement between RVC ≥10 percent and L-Dex increases above 6.5 was not only low but statistically insignificant, even showing a negative Cohen’s kappa value, indicating disagreement beyond chance. Even comparisons within or between measurements taken without baseline references only reached fair or moderate levels of agreement at best. This inconsistency means the different diagnostic tools often don't identify the same patients as having lymphedema, making it challenging for clinicians to decide on treatment approaches.

    Why does this variance occur? Measurement techniques differ in methodology and sensitivity. Tape measurements rely on centimeters of limb circumference, which may miss subtle fluid changes, while volume-based approaches aggregate multiple circumference points to estimate swelling. Optoelectronic volumetry uses infrared scanners to create a 3D image of limb volume with high precision, but availability and cost limit widespread clinical use. BIS offers a streamlined approach to detect extracellular fluid changes that precede visible swelling, yet its interpretation is dependent on comparison to a patient’s baseline and may vary across devices. The study’s findings emphasize this discrepancy, showing that depending on which tool and threshold a practitioner uses, the diagnosis of BCRL could differ—sometimes significantly.

    These findings underscore the urgent call for standardized diagnostic criteria for BCRL, as highlighted by Brunelle and colleagues. Without consensus, patients risk being misdiagnosed—either missing early intervention opportunities or facing unwarranted treatments. Interestingly, lymphedema research itself is evolving rapidly. For instance, wearable technology integrating smart sensors to monitor limb volume and fluid balance continuously is being explored, potentially revolutionizing early detection. Meanwhile, awareness campaigns and education about BCRL symptoms encourage patients to seek prompt evaluation, improving outcomes. This study not only sheds light on the technical hurdles in diagnosing BCRL but also opens the door for innovation and policy shaping in oncology rehabilitation.

    While the battle against breast cancer itself often takes center stage, complications like lymphedema quietly affect survivors’ long-term well-being. Understanding the nuances of diagnostic tools and striving for standardized, reliable criteria are vital steps toward improved management of BCRL. Future research must build on studies like this, considering patient-centered approaches and incorporating new technologies that can provide more accurate, accessible, and consistent diagnoses. For patients and clinicians alike, clarity in diagnosis is the foundation for effective treatment, better quality of life, and empowered survivorship in the journey beyond breast cancer.

    #BreastCancerAwareness #LymphedemaResearch #CancerSurvivorship #MedicalDiagnostics #RehabilitationOncology

    Source

  • PFE vs. MRK: Which Oncology Drug Giant is a Better Buy Now?

    In This Article:

    Merck MRK and Pfizer PFE are leading pharmaceutical companies with strong product and pipeline portfolios in oncology. Both companies also have presences in vaccines, neuroscience, and immunology.

    However. oncology accounts for more than 50% of Merck’s total revenues. Blockbuster PD-L1 inhibitor, Keytruda, approved for several types of cancers, alone accounts for around 50% of its pharmaceutical sales.

    As regards Pfizer, oncology sales comprise around 25% of its total revenues. Its position in oncology was strengthened with the acquisition of Seagen in 2023.

    Both companies are seeing consistent sales and earnings growth. Both boast robust pipelines with promising candidates in late-stage development. But which one is a better investment today? Let’s take a closer look at their fundamentals, growth prospects and challenges to make an informed choice.

    The Case for PFE

    Pfizer is one of the largest and most successful drugmakers in oncology. After witnessing possibly its worst slowdown in 2023/early 2024, the company seems to be gradually making a comeback and entering a transition phase. With its COVID-related uncertainties diminishing, its revenue volatility is declining.

    Though COVID revenues are declining, Pfizer’s non-COVID operational revenues improved in 2024, driven by its key in-line products like Vyndaqel, Padcev and Eliquis, new launches and newly acquired products like Nurtec and those from Seagen. The positive trend continued in the first quarter of 2025.

    The continued growth of Pfizer’s diversified portfolio of drugs, particularly oncology, should support top-line growth in 2025.

    Pfizer expects cost cuts and internal restructuring to deliver savings of $7.7 billion by the end of 2027. Pfizer’s significant cost-reduction and efforts to improve R&D productivity measures should drive profit growth.

    Pfizer faces its share of challenges, the key being declining sales of its COVID-19 products. Pfizer also expects a significant impact from the loss of patent exclusivity in the 2026-2030 period, as several of its key products, including Eliquis, Vyndaqel, Ibrance, Xeljanz and Xtandi, will face patent expirations. The Medicare Part D redesign is also expected to hurt sales of Pfizer’s higher-priced drugs like Vyndaqel, Ibrance and Xeljanz in 2025.

    The company has also faced its share of setbacks. Last month, Pfizer said it is discontinuing the development of its GLP-1R agonist, danuglipron, which was being developed as a weight loss pill. Pfizer took the decision after one of the participants in the dose-optimization studies developed a potentially drug-induced liver injury, which resolved after danuglipron was discontinued. Eli Lilly LLY and Novo Nordisk NVO currently dominate the obesity space.

    Also, uncertainties around tariffs and a volatile macro environment remain headwinds. Moreover, stocks of vaccine makers like Pfizer have been under pressure with the appointment of Robert F. Kennedy Jr., a well-known vaccine skeptic, as the Secretary of Health and Human Services (HHS).

    As of March 31, 2025, Pfizer had cash and cash equivalents of $17.3 billion on its balance sheet and $57.6 billion in long-term debt. Its debt-to-capital ratio of 0.41 is slightly higher than the industry's average of 0.38.

    The Case for MRK

    Merck boasts more than six blockbuster drugs in its portfolio, with Keytruda being the key top-line driver. Keytruda has played an instrumental role in driving Merck’s steady revenue growth in the past few years. Keytruda’s sales are gaining from rapid uptake across earlier-stage indications, mainly early-stage non-small cell lung cancer. Continued strong momentum in metastatic indications is also boosting sales growth. The company expects continued growth from Keytruda, particularly in early lung cancer. Merck is also developing a subcutaneous formulation of Keytruda that can extend its patent life. Merck is working on different strategies to drive Keytruda's long-term growth.

    Merck has been making meaningful regulatory and clinical progress across areas like oncology (mainly Keytruda), vaccines and infectious diseases while executing strategic business moves. Merck’s phase III pipeline has almost tripled since 2021, supported by in-house pipeline progress as well as the addition of candidates through M&A deals.

    Merck’s new products, Capvaxive and Winrevair, are witnessing strong launches and have the potential to generate significant revenues over the long term

    However, sales of Gardasil, which is Merck’s second-largest product, are declining due to a weak performance in China, which resulted from sluggish demand trends amid an economic slowdown. Merck is also seeing weakness in the diabetes franchise and the generic erosion of some drugs.

    Merck is heavily reliant on Keytruda. Though Keytruda may be Merck’s biggest strength and a solid reason to own the stock, it can also be argued that the company is excessively dependent on the drug and it should look for ways to diversify its product lineup.

    There are rising concerns about the firm’s ability to grow its non-oncology business ahead of the upcoming loss of exclusivity of Keytruda in 2028.

    Also, competitive pressure might increase for Keytruda in the near future.

    It exited 2024 with cash and cash equivalents of $9.2 billion against long-term debt of $33.5 billion, resulting in a debt-to-capital ratio of 0.41, which is higher than the industry's average of 0.38.

    How Do Estimates Compare for PFE & MRK?

    The Zacks Consensus Estimate for PFE’s 2025 sales implies a year-over-year decrease of 0.6% and 1%, respectively. EPS estimates for both 2025 and 2026 have risen over the past 60 days.

    PFE Estimate Movement

    Image Source: Zacks Investment Research

    The Zacks Consensus Estimate for MRK’s 2025 sales and EPS implies a year-over-year increase of 0.9% and 16.7%, respectively. EPS estimates for both 2025 and 2026 have declined over the past 60 days.

    MRK Estimate Movement

    Image Source: Zacks Investment Research

    Price Performance and Valuation of PFE & MRK

    Year to date, Pfizer’s stock has declined 10.8% and Merck’s stock has plunged 22.9% compared with the industry’s decrease of 4.0%

    Image Source: Zacks Investment Research

    Both MRK and PFE are priced lower than the industry from a valuation standpoint. MRK is more expensive than PFE, going by the price/earnings ratio. Merck’s shares currently trade at 8.24 forward earnings, higher than 7.41 for Pfizer.

    Image Source: Zacks Investment Research

    However, both Merck and Pfizer are cheaper than other large drugmakers like AbbVie, AstraZeneca, Eli Lilly and Novo Nordisk.

    Pfizer’s dividend yield of 7.5% is higher than MRK’s 4.3%.

    Image Source: Zacks Investment Research

    Pfizer’s return on equity of 20.3% is lower than Merck’s 43.2%

    PFE vs. MRK: Which is a Better Pick?

    The potential impact of tariffs imposed by the United States and some other countries is a concern. Although both Pfizer and Merck’s 2025 earnings guidance accounts for the impact of tariffs already in place, the potential expansion of tariffs in other geographies or increases in retaliatory tariffs would have a negative impact. Though pharmaceuticals have been exempted from tariffs this time around, they could well be Trump’s target in the next round, considering the President’s goal to shift pharmaceutical production back to the United States, mostly from European and Asian countries.

    However, both Pfizer and Merck said on their respective first-quarter conference calls that if the import tariffs are implemented on pharmaceutical products, they are well placed to manage the impact.

    Trump and the Republican government also continue to stress on the control of drug prices with the latest attempt being his “most favored nations’ policy.”

    Merck has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

    Merck has one of the world’s best-selling drugs in its portfolio, generating billions of dollars in revenues. Though Keytruda will lose patent exclusivity in 2028, its sales are expected to remain strong until then. However, the company’s problems are too many at present, including persistent challenges for Gardasil in China, potential competition for Keytruda and rising competitive and generic pressure on some drugs. All these factors have raised doubts about Merck’s ability to navigate the Keytruda loss of exclusivity period successfully. Consistently declining estimates also reflect analysts’ pessimistic outlook for the stock.

    Pfizer, on the other hand, with its improving growth prospects, rising estimates, cheaper valuation, and higher dividend yield, is a better bargain for investors looking to invest in drug/biotech stocks with higher growth potential. Pfizer, with a Zacks Rank #2 (Buy), is a clear-cut winner.

    Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

    Pfizer Inc. (PFE) : Free Stock Analysis Report

    Novo Nordisk A/S (NVO) : Free Stock Analysis Report

    Merck & Co., Inc. (MRK) : Free Stock Analysis Report

    Eli Lilly and Company (LLY) : Free Stock Analysis Report

    This article originally published on Zacks Investment Research (zacks.com).

    Zacks Investment Research

    Recommended Stories

  • One of the top cancer treatment centers is now open in North Augusta

    In the heart of North Augusta, South Carolina, progress is visibly taking shape with the Beacon Bluff Project nearing its anticipated completion. Originally slated to wrap up shortly after the Masters Week in early spring, the project's developer, Palmetto Peach Development, had signaled optimism about finalizing the core shell of the development by late March. While the main construction work has kept tight schedules, attention has now pivoted to an equally vital neighbor: a long-anticipated cancer treatment facility set in the former Medac building next door. This facility, now under Augusta Oncology Multispecialty Clinics, marks a significant milestone for the community by providing essential healthcare services that were once distant and arduous for many patients.

    From what was a familiar yet underutilized space with Medac employees, the building is transforming into a cutting-edge $30 million facility that amalgamates radiology and oncology services under one roof. Augusta Oncology’s presence is not just symbolic but practical — expected to create approximately 100 new jobs, it also promises compassionate, advanced care for patients battling cancer in the region. For individuals like Nancy Kitchens, a breast cancer survivor, the local facility is more than just a treatment center; it’s a beacon of hope. Nancy's journey underscores the emotional and logistical trials faced by cancer patients. Thanks to the proximity of Augusta Oncology, Nancy has been relieved from the burden of balancing her treatment demands with work and family responsibilities, eliminating the need for exhausting long-distance travel for her medical care.

    The genesis of this advanced oncology facility was facilitated by South Carolina’s repeal of the certificate of need (CON) law—a regulatory framework that once limited the number and location of healthcare services within the state. This regulatory relaxation allowed Augusta Oncology to introduce top-tier technology and services, including two state-of-the-art radiation therapy machines. Bailey Scifleet, the director of finance at Augusta Oncology, highlights the sophistication of the equipment, emphasizing how it represents the pinnacle of current healthcare technology. Imagine a sleek, almost spaceship-like apparatus meticulously targeting cancer cells with precision — a remarkable leap forward from older, less efficient treatments. This precision not only improves effectiveness but also minimizes discomfort, as Nancy recounts her pain-free experiences during radiation sessions, where the machine gently adjusts her body in tiny increments to zero in on the affected area.

    Nancy’s story uniquely captures the emotional complexity of a cancer diagnosis. The initial shock and the avalanche of questions—“How will this be done? How will we afford it? What can we do?”—reflect a common narrative among patients facing this daunting journey. Yet, within this struggle, the quality of care and the unwavering support from her medical team have been transformative. When a doctor reassures a patient with confidence and expertise, it doesn’t just convey medical facts; it instills courage and a fighting spirit. Nancy’s optimism, bolstered by the leading-edge treatment and empathetic care she receives at Augusta Oncology, is a testament to how integrated and innovative healthcare services can profoundly impact patient outcomes and quality of life.

    While the patient benefits are profound, the establishment of Augusta Oncology also symbolizes a triumph of community-centered development. Spearheaded by North Augusta Forward and funded without tapping into city or taxpayer dollars, this project illustrates how strategic partnerships and local initiative can foster vital infrastructure improvement. Although supply chain disruptions delayed the timeline past the initially expected completion in February 2024, progress remains steady and promises to bring relief and opportunity to the area’s residents and businesses. The return on investment here extends beyond economics—it’s measured in lives touched, hope renewed, and a future where advanced medical care is accessible without the added stress of travel. As North Augusta inches closer to the full completion of the Beacon Bluff project’s core shell, the synergy between development and healthcare innovation paints a hopeful picture for this dynamic community.

    #BeaconBluff #AugustaOncology #CancerCare #HealthcareInnovation #NorthAugustaSC #MedicalTechnology #CommunityDevelopment

    Source

  • Mainland Chinese drug effective in treating 3 cancer types: Hong Kong-led study

    University researchers said on Monday that the novel drug, D3S-001, had shown promising results in treating non-small cell lung, colorectal and pancreatic cancers triggered by the gene mutation KRAS-G12C during its phase one clinical trial.

    The drug is said to be a “next-generation” inhibitor for the gene mutation, which can currently only be targeted using a limited number of therapeutic options.

    “It does inhibit KRAS-G12C at a quicker rate [than a first-generation inhibitor] and most likely at a longer duration as well,” said Dr Herbert Loong Ho-fung, an associate professor at CUHK’s clinical oncology department.

    “This is demonstrated in the laboratory and certainly in our clinical trials. We’re also seeing signals of this in our patients.”

    Researchers said KRAS gene mutations were common contributing factors in solid tumours including non-small cell lung, colorectal and pancreatic cancers, with KRAS-G12C being the most prevalent subtype.

  • Annual Immuno-Oncology Summit

    The upcoming summit promises to be a landmark event for professionals and enthusiasts in the fields of biotechnology, immunotherapy, and pharmaceutical innovation. This comprehensive conference will delve into a vast array of pioneering topics, providing attendees with insights into cutting-edge research and breakthrough therapies that have the potential to revolutionize the treatment of cancer, autoimmune diseases, and other challenging medical conditions. By focusing on the nuances of bi- and multispecific engineering, advanced antibody-drug conjugates, and novel cell therapy approaches, the summit aims to bridge the gap between laboratory innovation and clinical success, fostering collaboration and knowledge-sharing across the industry.

    Of particular interest is the exploration of bi- and multispecific engineering, where participants will examine the role of nanobody applications and the functional design of bispecific antibodies. These customizable molecules are engineered to bind simultaneously to two or more targets, offering improved specificity and efficacy, especially in treating solid tumors—a historically difficult area for immunotherapies. The summit will unpack strategies for choosing the right targets and refining engineering methods to create therapies that not only attack cancer cells more precisely but also minimize side effects. Fun fact: nanobodies, derived from camelid antibodies, are significantly smaller than traditional antibodies and can penetrate tissues more effectively, enabling therapies that may reach cancer cells previously out of therapeutic reach.

    Equally captivating is the focus on translating multispecific success into real-world treatments through the integration of cellular modalities like CAR T cells and TILs (tumor-infiltrating lymphocytes). By leveraging machine learning algorithms, researchers can now predict optimal therapeutic combinations and anticipate potential safety challenges before clinical trials, reducing costly setbacks. The discussion will extend to regulatory hurdles, an essential consideration as therapies become more complex and personalized. Interestingly, the use of machine learning in drug development is akin to having a microscopic detective team analyzing molecular interactions and clinical data to fast-track promising candidates while ensuring patient safety—a growing trend that's reshaping biopharma R&D.

    Antibody-drug conjugates (ADCs) remain a focal point given their unique mechanism of delivering potent cytotoxic agents directly to cancer cells, sparing healthy tissues. Breakthroughs in linker technology—the part that connects the antibody to the drug payload—are enabling more stable and precisely timed release of therapeutics. Site-specific conjugation techniques have also evolved, allowing for uniform ADC products that maximize efficacy and minimize toxicity. Tackling resistance mechanisms continues to be a critical challenge, making this summit session invaluable for those dedicated to overcoming therapeutic hurdles. Here's an intriguing tidbit: the first FDA-approved ADC, ado-trastuzumab emtansine (Kadcyla), revolutionized HER2-positive breast cancer treatment by combining targeted therapy with chemotherapy in a single molecule.

    Breaking new ground in cell therapy, the summit will spotlight exciting advancements in CAR T cell therapies tailored for solid tumors—a field that has lagged behind success seen in blood cancers. The incorporation of tumor-infiltrating lymphocytes (TILs), T cell receptors (TCRs), and regulatory T cells (Tregs) for modulating immune responses offers new hope for durable cancer control. Combining multiple cell therapies and addressing clinical attrition—where promising therapies fail in late-stage trials—remains a priority to enhance patient outcomes. Moreover, transient therapeutic approaches and the application of insights from immuno-oncology to autoimmune diseases promise to broaden the impact of these innovative treatments. As a quirky fact, while CAR T cell therapy was initially personalized for each patient, recent research is exploring “off-the-shelf” allogeneic products to make this life-saving therapy more accessible globally.

    Lastly, the summit will tackle the complex world of innate immunity and its role in solid tumor biology. Key topics include developments in natural killer (NK) cell engagers and gamma delta T cell innovations, both pivotal components of the body's first line of defense against cancer. Enhancements in translatable models—systems that better predict human responses—combined with machine learning and data science applications, are accelerating the progress toward more effective immunotherapies. This area of research is fascinating because it taps into the body’s ancient defense mechanisms but engineers them to provide smart, targeted responses against modern-day diseases like cancer. Did you know that gamma delta T cells constitute only 1-5% of circulating T cells yet have potent anti-tumor activity, making them an exciting frontier for next-generation therapies?

    For those captivated by the rapidly evolving landscape of biotech and pharma, signing up for daily email updates from industry leaders will provide a convenient and insightful way to stay informed on the latest developments. This summit is not just a meeting of minds but a gateway to future breakthroughs that could fundamentally transform patient care worldwide. Whether you are a researcher, clinician, investor, or simply a biotech enthusiast, the knowledge shared here will empower you to grasp and contribute to the innovations shaping tomorrow’s medicine.

    #BiotechInnovation #Immunotherapy #CellTherapy #AntibodyDrugConjugates #CancerResearch #MachineLearningInMedicine #PharmaBreakthroughs

    Source

  • Psychological Stress Biomarker Levels Found Higher in Neuro-Oncology Caregivers

    Caring for a loved one diagnosed with a primary malignant brain tumor is a profound challenge that extends far beyond managing medical appointments and medication schedules. It encompasses emotional turmoil, lifestyle changes, and often a significant psychological burden borne by the caregivers themselves. A recent study published in Cancer Nursing sheds light on an intriguing biological marker, C-reactive protein (CRP), which provides a window into the stress levels experienced by these caregivers. CRP is a substance produced by the liver in response to inflammation and has long been recognized as a marker for infection and chronic conditions. However, this study underscores its emerging role as a biomarker for psychological stress, revealing how deeply caregiving responsibilities can affect physical health.

    The diagnosis of a primary malignant brain tumor invariably disrupts a patient’s quality of life and independence. Malignant brain tumors are particularly devastating due to their impact on cognitive functions, reducing a patient’s ability to perform everyday tasks and make decisions. These challenges mean that caregiving duties are not only intensive but complex, often requiring vigilance, patience, and profound emotional resilience. According to research, neuro-oncology caregivers may endure stress levels even more acute than those experienced by caregivers of other cancer patients. This chronic psychological stress, if left unaddressed, can precipitate detrimental health outcomes, increasing the risk of illnesses that range from cardiovascular disease to depression, and even accelerating the caregiver’s decline in immune function and overall well-being.

    To delve deeper into these health impacts, researchers analyzed data from a study that offered cognitive behavioral therapy (CBT) targeted specifically at neuro-oncology caregivers. The study enrolled 80 individuals, who were split into two groups: one accessed enhanced usual care, primarily through a website providing stress-coping resources, while the other underwent a more immersive SmartCare intervention. This eight-week program involved structured problem-solving advice, self-help assignments accessible on the SmartCare website, and personalized support through nurse phone counseling. The program aimed to equip caregivers with practical tools to address personal stressors, enhance their coping mechanisms, and ultimately alleviate physiological markers of stress such as CRP.

    The results were compelling. Caregivers participating in the SmartCare intervention exhibited a decrease in mean CRP levels—from 1.11 at the start to 0.88 after four months—signifying a reduction in systemic inflammation linked to psychological stress. Meanwhile, those in the control group, with access only to general coping information, experienced a rise in CRP levels from 0.63 to 1.30, indicating an increased inflammatory burden. Furthermore, cardiovascular risk, inferred from CRP levels, shifted alarmingly in the control group where half the caregivers moved from lower- to higher-risk categories. Comparatively, just 11% of those receiving the SmartCare intervention experienced such a transition. This stark divergence accentuates the importance of proactive psychological support for caregivers, not only to safeguard mental health but also physical well-being.

    What makes the findings even more fascinating is the potential wider application of CRP monitoring in caregiving contexts. If CRP levels can be reliably linked with psychological stress, monitoring this marker could serve as an early warning system to identify caregivers at risk before clinical symptoms manifest. This could revolutionize caregiver support by introducing objective physiological assessments that complement traditional psychological evaluations. On a slightly whimsical note, did you know that CRP was first discovered back in 1930? It got its name because it reacts to the C-polysaccharide of pneumococcus bacteria, highlighting how a biomarker initially tied to infection is now being applied to the subtle realm of psychological stress. This intersection between physical biomarkers and mental health reflects an exciting frontier in healthcare, bridging bridging biology and the intangible human experience.

    In summary, the research confirms that caregiving for patients with malignant brain tumors induces measurable stress that impacts caregivers’ inflammation levels and cardiovascular health risk. The success of the SmartCare intervention illustrates the power of tailored psychological strategies combined with personal support to not only alleviate caregiver stress but materially improve their physiological wellbeing. As the healthcare community seeks to develop holistic approaches to cancer care, integrating caregiver-centric programs that monitor and mitigate stress-induced inflammation could become standard practice. Caregivers might indeed become the “hidden patients” whose health struggles need recognition and targeted intervention. After all, ensuring their well-being is not only an act of compassion but a crucial component for sustaining the entire continuum of care.

    #CaregiverHealth #BrainTumorAwareness #PsychologicalStress #CReactiveProtein #NeuroOncology #SmartCareIntervention #MentalHealthMatters

    Source